XML 39 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statement of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net loss $ (75,332) $ (72,040)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 99 88
Unrealized foreign currency (gain) loss (91) 712
Stock-based compensation 6,542 5,464
Change in fair value of tranche rights 4,796 0
Fees expensed as part of January 2024 Financing 1,690 0
Changes in operating assets and liabilities:    
Other current assets and prepaid expenses 1,460 3,881
Accounts payable 871 (951)
Accrued expenses (1,900) 5,961
Other liabilities 62 84
Net cash used in operating activities (61,803) (56,801)
Cash flows from investing activities:    
Purchases of property and equipment (261) (169)
Sale of investments - Other 0 9,796
Net cash provided by (used in) investing activities (261) 9,627
Cash flows from financing activities:    
Proceeds from public offering of common stock through At The Market Sales Agreement, net 191 282
Proceeds from January 2024 Financing, net of issuance costs 74,273 0
Proceeds from the exercise of pre-funded warrants 0 51
Proceeds from shares issued in connection with the Company's Employee Stock Purchase Plan 0 96
Net cash provided by financing activities 74,464 429
Effect of exchange rate changes on cash and cash equivalents (3) (311)
Net change in cash and cash equivalents 12,397 (47,056)
Cash and cash equivalents, beginning of period 46,674 106,745
Cash and cash equivalents, end of period 59,071 59,689
Supplemental disclosure of noncash investing and financing activities:    
Conversion of tranche rights liability to equity upon increase in authorized shares 28,396 0
Operating lease right-of use asset obtained in exchange for lease obligation $ 0 $ 544